Design & Development of Antibodies to Complex Targets

SDIX hosted a series of webinars focused on how to Design and Develop Antibodies to Complex Targets. You can view the webinars by clicking on the links below.

Overview: While the requirement for better antibodies has grown exponentially in recent years, the ability to develop these antibodies has lagged behind this need. At SDIX, a focus on the philosophy of better antigen design has resulted in dramatic improvements to the antibody production process.

In a series of talks, SDIX scientists will discuss this antigen design philosophy and provide case studies to demonstrate the effectiveness of this methodology. In particular, these talks will focus on the use of SDIX’s proprietary Genomic Antibody Technology™ and its ability to deliver antibodies that match end users’ requirements.

Date and Time	Topic	Presenter

Available to Watch Now	An Introduction to SDIX's Technology An introduction to SDIX and our core technology, available to watch now. Discover why our technology demonstrates a powerful, fundamental improvement over conventional antibody technologies (ex. peptide and full length proteins).
Available to Watch Now	Design and Development of Antibodies to Complex Protein Targets for Critical Assay Applications James Stave, PhD, Senior Research Fellow, SDIX Examination of functional and therapeutic antibody-antigen x-ray crystal structures provides critical insight into B-cell epitope architecture. The size of an antibody ‘footprint’ determines the number of antigen amino acid residues contacted by the antibody. Antigen contact residues are organized into long linear sequence spans similar in size to protein domains. The assay format that an antibody reagent is intended to be used in influences antigen structure. Knowledge of antigen and antibody structure as well as the intended assay format and application dictate the strategy of antigen design, immunization and, antibody screening protocols. SDIX Genomic Antibody Technology™ is designed for development of antibodies that recognize conformational epitopes in critical assay formats such as sandwich immunoassays and flow cytometry and, enables targeting of antibodies to specific sites of native proteins. Antigen and antibody design strategies useful for different assay formats and classes of protein targets, including secreted and multipass membrane proteins are discussed.
Available to Watch Now	Comparing the Performance of Antibodies Generated From Peptide and DNA-Encoded Antigens Ross Chambers, PhD, Director, Technology R&D, SDIX Antigens are a critical factor in the success of an antibody development project and can influence the amount of antibody and the performance characteristics. Short (~15aa) synthetic peptides are one of the most popular antigens for generating antibody reagents and has been used to generate most catalog antibody collections. The dirty little secret of the antibody world is that most antibodies do not work or are highly restricted to working in a few immunoassay applications. This problem is especially acute for antibodies that can recognize folded protein (eg sandwich ELISAs). We have recently developed a DNA immunization-based technology for generating antibodies in mice and rabbits called Genomic Antibody Technology. This method delivers large folded fragments (~150aa) of target proteins as antigens to produce with a high success rate antibodies that can work in a range if immunoassays including sandwich ELISA. Here we will discuss a large study where we generated comparative data on the performance of antibodies generated by the two methods.
Available to Watch Now	The Importance of Immunogen Selection for Successful Antibodies David Fancy, PhD, Senior R&D Scientist, SDIX A key activity in developing an antibody that works in the intended assay is the selection of an appropriate immunogen. In this webinar, antigen design will be discussed. The relative advantages and disadvantages of using synthetic vs. recombinant protein immunogens will be addressed as well as the concepts and tools used to determine antigenic regions will be considered. Ultimately, a successful antibody development program can hinge on antigen design and is a critical first step.